‘We won’t have to do those dinosaur trials.’ How new cancer drugs can skip randomized tests

Research that fine-tune treatments to the genetic profile of patients, is fuelling a rethink over how new cancer drugs are tested. The promise: medicines that, in theory at least, can win approval more easily and cheaply. That also raises ethical questions. Read more here.